Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Products under Development by Stage of Development | 7 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Products under Development by Therapy Area | 8 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Products under Development by Indication | 9 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Pipeline Products Glance | 10 | 1 |
| Early Stage Products | 10 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Products under Development by Companies | 11 | 2 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Products under Development by Universities/Institutes | 13 | 2 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Therapeutics Assessment | 15 | 5 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Companies Involved in Therapeutics Development | 20 | 3 |
| Carna Biosciences, Inc. | 20 | 1 |
| NeuroNascent, Inc. | 21 | 1 |
| Selvita S.A. | 22 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Drug Profiles | 23 | 7 |
| Harmine Drug Profile | 23 | 1 |
| NNI-351 Drug Profile | 24 | 1 |
| PST-900 Drug Profile | 25 | 1 |
| SEL-141 Drug Profile | 26 | 1 |
| Small Molecule to inhibit DYRK1A for CNS Diseases Drug Profile | 27 | 1 |
| Small Molecule to Inhibit DYRK1A for Neurodegenerative Diseases Drug Profile | 28 | 1 |
| Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease Drug Profile | 29 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Dormant Projects | 30 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Discontinued Products | 31 | 1 |
| Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or EC 2.7.12.1) Featured News &Press Releases | 32 | 1 |
| Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics | 32 | 1 |
| Mar 20, 2013: BIO5-TGen Collaboration Focused On Drug Development For Alzheimer s Disease | 32 | 1 |
| Appendix | 33 | 2 |
| Methodology | 33 | 1 |
| Coverage | 33 | 1 |
| Secondary Research | 33 | 1 |
| Primary Research | 33 | 1 |
| Expert Panel Validation | 33 | 1 |
| Contact Us | 33 | 1 |
| Disclaimer | 34 | 1 |